Abstract:Senescence refers to a cellular state featuring a stable cell‐cycle arrest triggered in response to stress. This response also involves other distinct morphological and intracellular changes including alterations in gene expression and epigenetic modifications, elevated macromolecular damage, metabolism deregulation, and a complex proinflammatory secretory phenotype. The initial demonstration of oncogene‐induced senescence in vitro established senescence as an important tumour suppressive mechanism, in addition to apoptosis. Senescence not only halts the proliferation of premalignant cells but also facilitates the clearance of affected cells through immunosurveillance. Failure to clear senescent cells owing to deficient immunosurveillance may, however, lead to a state of chronic inflammation that nurtures a pro‐tumorigenic microenvironment favouring cancer initiation, migration, and metastasis. In addition, senescence is a response to post‐therapy genotoxic stress. Therefore, tracking the emergence of senescent cells becomes pivotal to detect potential pro‐tumorigenic events. Current protocols for the in vivo detection of senescence require the analysis of fixed or deep‐frozen tissues, despite a significant clinical need for real‐time bioimaging methods. Accuracy and efficiency of senescence detection is further hampered by a lack of universal and more specific senescence biomarkers. Recently, in an attempt to overcome these hurdles, an assortment of detection tools have been developed. These strategies all have significant potential for clinical utilization, and include flow cytometry combined with histo‐ or cytochemical approaches, nanoparticle‐based targeted delivery of imaging contrast agents, OFF‐ON fluorescent senoprobes, positron emission tomography (PET) senoprobes, and analysis of circulating SASP factors, extracellular vesicles, and cell‐free nucleic acids isolated from plasma. Here we highlight the occurrence of senescence in neoplasia and advanced tumours, assess the impact of senescence on tumorigenesis, and discuss how the ongoing development of senescence detection tools might improve early detection of multiple cancers and response to therapy in the near future.

Detecting senescence: a new method for an old pigment

Robust, universal biomarker assay to detect senescent cells in biological specimens

Senescence detection using reflected light

Simple Detection Methods for Senescent Cells: Opportunities and Challenges

A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Quantitative identification of senescent cells in aging and disease

Recent Developments in Small-Molecule Fluorescent Probes for Cellular Senescence

A Tandemly Activated Fluorescence Probe for Detecting Senescent Cells with Improved Selectivity by Targeting a Biomarker Combination.

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

A Fully-Automated Senescence Test (FAST) for the high-throughput quantification of senescence-associated markers

SenNet recommendations for detecting senescent cells in different tissues

An Activatable NIR Probe for the Detection and Elimination of Senescent Cells

Skin Color Independent Assessment of Aging Using Skin Autofluorescence.

A rapid-response near-infrared fluorescent probe with a large Stokes shift for senescence-associated β-galactosidase activity detection and imaging of senescent cells

A rationally designed fluorescence probe achieves highly specific and long‐term detection of senescence in vitro and in vivo

Methods for detection of mitochondrial reactive oxygen species in senescent cells

Ratiometric Fluorescent Probe for Real-Time Detection of β-Galactosidase Activity in Lysosomes and Its Application in Drug-Induced Senescence Imaging

Noninvasive NIR Imaging of Senescence via In Situ Labeling

Cellular senescence in cancer: from mechanisms to detection

Is Senescence-Associated β-Galactosidase a Reliable in vivo Marker of Cellular Senescence During Embryonic Development?